InvestorsHub Logo
Followers 59
Posts 11479
Boards Moderated 0
Alias Born 07/16/2006

Re: Jesspro post# 79415

Wednesday, 12/07/2016 4:39:20 AM

Wednesday, December 07, 2016 4:39:20 AM

Post# of 80490
Jesspro,

Am I just reading it wrong?



Yes. Novartis's drug Ceritinib is actually a couple of steps behind Brig.
You can't make comparison between the drugs at this point because the Novartis trial is for 1st line usage, in other words the patients haven't been compromised with any other drugs prior to this test.

Brig on the other hand had patients that already have failed many other drugs already.

The only data we have to compare to Novartis's trial would be the 8 patients from the phase 1/2 trial who were uncompromised. At last report only 2 of the 8 progressed at 24 months while all were alive at 24 months. Novartis's trial reported pfs at 16 months.

3 of these 8 patients obtained a CR which is very critical going forward.

As a note Ceritinib did have a encouraging result if the patient didn't have brain mets. (26.3 mos)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.